Company: EUDAW
Filing Date: 2025-04-29
Form Type: 20-F
Source: 0001641172-25-006627
Chunk: 108

Company: EUDA Health Holdings Ltd
Filing Date: 2025-04-29
Form: 20-F
Item: Item 16
Chunk 108
---

 
Anti-takeover Provisions in Our Memorandum of association and articles of association
 
Some provisions of our memorandum of association and articles of association may discourage, delay or prevent a change in control of our company or management that shareholders may consider favorable, including provisions that authorize our board of directors to issue shares in manner, on the terms and conditions and for the issue prices that the directors may determine.
 
Foreign Private Issuer Exemption
 
As a British Virgin Islands company listed on the Nasdaq Capital Market, we are subject to the Nasdaq Stock Market Rules corporate governance listing standards. However, Nasdaq Stock Market Rules permit a foreign private issuer like us to follow the corporate governance practices of its home country. Certain corporate governance practices in British Virgin Island, which is our home country, may differ significantly from the Nasdaq Stock Market Rules. While we voluntarily follow most Nasdaq corporate governance rules, we may choose to take advantage of the following exemptions afforded to foreign private issuers:

●                                             exemption                                          
       from the requirement to obtain shareholder approval for certain issuances of securities,  
       including shareholder approval prior to certain dilutive events, including a transaction  
       other than a public offering involving the sale of 20% or more of the issuer’s ordinary   
    shares outstanding prior to the transaction for less than the greater of book or market value
    of the shares, or the issuance of ordinary shares issuable upon conversion of the convertible
                                              notes; and                                         
-------------------------------------------------------------------------------------------------

●                                          exemption                                        
    from the requirement that our board of directors shall have regularly scheduled meetings
    at which only independent directors are present as set forth in Nasdaq Rule 5605(b)(2). 
--------------------------------------------------------------------------------------------

70
--
 

We intend to follow our home country practices in lieu of the foregoing requirements. Although we may rely on home country corporate governance practices in lieu of certain of the rules in the Nasdaq Rule 5600 Series and Rule 5250(d), we must comply with Nasdaq’s Notification of Noncompliance requirement (Rule 5625), the Voting Rights requirement (Rule 5640) and have an audit committee that satisfies Rule 5605(c)(3), consisting of committee members that meet the independence requirements of Rule 5605(c)(2)(A)(ii). Although we currently intend to comply with the Nasdaq corporate governance rules applicable other than as noted above, we may in the future decide to use the foreign private issuer exemption with respect to some or all the other Nasdaq corporate governance rules. As a result,